anti-CD5 CAR T cells

Anti-CD5 CAR T cells are genetically engineered T lymphocytes that express a chimeric antigen receptor (CAR) targeting the CD5 protein, a pan-T cell surface marker present on most malignant and normal T-cells. These therapies can be manufactured from either autologous (patient-derived) or allogeneic (donor-derived) sources. The primary mechanism involves redirecting the cytotoxic activity of modified T-cells to recognize and eliminate CD5-expressing malignant cells, such as those found in relapsed or refractory mature T-cell lymphoma (TCL) and acute lymphoblastic leukemia (T-ALL). To overcome fratricide—a challenge where engineered CAR-Ts attack each other due to shared antigens—CD5 CAR constructs induce downregulation of surface CD5 on transduced cells, minimizing self-targeting while maintaining potent antitumor effects. Clinical studies have shown promising safety profiles with low-grade cytokine release syndrome and neurotoxicity, as well as clinical responses in patients with relapsed/refractory TCL[1][3][4][5][6].

Other names

Anti-CD5 CAR T-cell therapyAnti-CD-5 CAR T-cell therapyAnti-CD 5 CAR T-cell therapyallogeneic anti-CD5 CAR T cellsautologous CD5.CAR T cells